Resistance to Ibritumomab in Lymphoma

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumom...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Hosono, Makoto (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt), Chatal, Jean-François (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2018.
Έκδοση:1st ed. 2018.
Σειρά:Resistance to Targeted Anti-Cancer Therapeutics, 18
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
Πίνακας περιεχομένων:
  • Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma
  • Biology and Pathology of B-cell lymphoma
  • Resistance to Y-90 Ibritumomab Tiuxetan Therapy
  • Features of Ibritumomab as Radionuclide Therapy
  • Radiological Evaluation of Response and Resistance of Ibritumomab
  • Characteristics of Ibritumomab as Radionuclide Therapy Agent
  • Resistance and Heterogeneity of Intratumoral Antibody Distribution
  • Radiation Dosimetry in Ibritumomab Therapy
  • Combining RAIT and immune-based therapies to overcome resistance in cancer?
  • Prospects for enhancing efficacy of radioimmunotherapy
  • Index.